Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayRoche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to Share XTecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayhttps://pharmaphorum.com/news/tecentriq-can-stay-as-therapy-for-triple-negative-breast-cancer-fda-experts-say/
Enhertu cleared for NHS use via Cancer Drugs FundNICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the Share XEnhertu cleared for NHS use via Cancer Drugs Fundhttps://pharmaphorum.com/news/enhertu-cleared-for-nhs-use-via-cancer-drugs-fund/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
NICE okays regular NHS funding for Novartis’ breast cancer drug KisqaliNICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously Share XNICE okays regular NHS funding for Novartis’ breast cancer drug Kisqalihttps://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
ANGLE raises £20m, eyes opportunity in immunotherapy trialsLiquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will Share XANGLE raises £20m, eyes opportunity in immunotherapy trialshttps://pharmaphorum.com/news/angle-raises-20m-eyes-opportunity-for-parsortix-in-immunotherapy-trials/
